MTHFR C677T polymorphism is associated with methotrexate-induced myelopathy risk

Neurology. 2017 Feb 7;88(6):603-604. doi: 10.1212/WNL.0000000000003590. Epub 2017 Jan 6.

Authors

Kelsey Juster-Switlyk¹, A Gordon Smith¹, Tibor Kovacsovics¹, Deborah Stephens¹, Martha Glenn¹, Cheryl Ann Palmer¹, Edward P Quigley 3rd¹, Noah Kolb²

Affiliations

¹ From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington.
² From the University of Utah (K.J.-S., A.G.S., T.K., D.S., M.G., E.P.Q.); Huntsman Cancer Institute (C.A.P.), Salt Lake City, UT; and University of Vermont Medical Center (N.K.), Burlington. [email protected].

No abstract available

Publication types

Case Reports

MeSH terms

Antimetabolites, Antineoplastic / adverse effects
Female
Humans
Male
Methotrexate / adverse effects*
Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
Middle Aged
Polymorphism, Single Nucleotide / genetics*
Risk Factors
Spinal Cord Diseases / chemically induced*
Spinal Cord Diseases / diagnostic imaging
Spinal Cord Diseases / genetics*

Substances

Antimetabolites, Antineoplastic
MTHFR protein, human
Methylenetetrahydrofolate Reductase (NADPH2)
Methotrexate